Ratings Molecular Partners AG Nasdaq

Equities

MOLN

US60853G1067

Market Closed - Nasdaq Other stock markets 20:47:09 28/06/2024 BST			5-day change	1st Jan Change
7.23 ^USD	+2.53%		-24.69%	+72.97%

06-20	Top Premarket Gainers	MT
06-17	Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MOLECULAR PARTNERS AG	+72.97%	235M	-
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	122B	B+
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B	B+
ARGENX SE	+18.95%	26.49B	B
BIONTECH SE	-23.86%	19.4B	B+
GENMAB A/S	-19.03%	16.24B	A-
BEIGENE, LTD.	-20.90%	15.4B	B
WUXI APPTEC CO., LTD.	-46.14%	15.15B	A-
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B	C+
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.52B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes